Viking Therapeutics: 'Strong Buy' On Injectable VK2735 Maintenance Data And Treatment Optionality

Viking Therapeutics retained a Strong Buy rating following positive Phase 2 and maintenance data for obesity drug candidate VK2735. Subcutaneous VK2735 maintained weight loss in 97% of every-other-week patients and 90% of monthly-dosing patients, supporting potential differentiation in the GLP-1/GIP obesity market. Phase 3 injectable studies are ongoing, while Phase 3 oral studies are expected to begin in Q4 2026.

Analysis

VKTX’s investability is increasingly a durability-and-convenience thesis rather than a headline efficacy thesis. Less frequent maintenance dosing could support superior persistence, lower discontinuation, and potentially better net pricing than weekly-only peers; however, this advantage must survive larger, longer pivotal studies and demonstrate that exposure does not create tolerability or lean-mass trade-offs. The relevant competitive set is not only LLY and NVO, but next-generation obesity developers such as ALT, AMGN and RYTM, where differentiation is being priced on dosing burden, weight-loss maintenance and manufacturing scalability rather than initial weight-loss percentages alone.

Near term, the stock is likely to trade as a high-beta clinical-development and strategic-optionality asset: positive pivotal execution can expand the probability-weighted value sharply, while any enrollment delay, discontinuation signal, or less compelling maintenance data would compress both standalone and takeout value. Over 6-18 months, the oral program is strategically important because payer access will favor lower-cost, scalable formulations, but its later timeline means it should receive limited present-value credit today. Consensus may be underestimating the risk that large incumbents use rebates, distribution control and combination regimens to make clinical differentiation insufficient for commercial share.

The non-obvious upside is M&A: a credible low-frequency injectable platform plus an oral follow-on could be more valuable to a company lacking an obesity franchise than to public-market investors underwriting serial trial risk. Conversely, a broad sector derating in obesity after safety, reimbursement, or supply normalization could hurt VKTX disproportionately because it lacks commercial cash flows to cushion multiple compression.

Key Decisions for Investors

• Maintain a tactical long VKTX only while pivotal-study execution remains on schedule; size as a binary clinical-risk position rather than a core healthcare holding. Reassess immediately on enrollment timing, discontinuation rates, body-composition data, or any guidance implying slippage; these are more thesis-relevant than routine analyst-rating changes.
• For a 3-9 month expression, prefer a defined-risk VKTX call spread rather than outright shares if implied volatility is below the expected value of pivotal or strategic catalysts. Use strikes around the current spot and a 30-50% upside cap; the trade requires verification that the catalyst falls within the option tenor and that premium outlay is not already pricing a takeout scenario.
• Pair a modest long VKTX against short XBI only if company-specific catalyst visibility improves, isolating execution and M&A optionality from biotech-beta risk. Exit if XBI materially outperforms on falling-rate or risk-on flows without corresponding VKTX relative strength, which would signal that idiosyncratic differentiation is not being rewarded.
• Do not underwrite meaningful oral-program value until pivotal design, dose selection, manufacturing economics and comparative tolerability are disclosed. A delay beyond the stated initiation window or an oral profile that fails to show a convenience, efficacy, or cost advantage would reduce the platform valuation and weaken strategic-buyer interest.